Chief Executive Officer, New York
Kenneth Frazier’s appointment as Merck’s CEO in 2011 came with a tough decision: Cut R&D investment to keep financial projections intact or dial back the company’s EPS targets to maintain research funding. He made the decision that ruffled Wall Street but held true to his company’s commitment to science: “To me, it felt wrong to cut our company’s core just for short-term investor gain,” he recalled in late October.
In honor of Ken’s appointment as the 2021 CEO of the Year, AlixPartners CEO Simon Freakley reflects on Ken’s leadership while at Merck in a time of ongoing disruption and global challenges and shares other observations from the ceremony celebrating Ken’s achievements.
Read the full article on Simon’s LinkedIn.